Oncos Therapeutics names new CMO
This article was originally published in Scrip
Executive Summary
Oncos Therapeutics, a Helsinki, Finland-based biotech company developing cancer therapeutics based on its next-generation oncolytic viruses, has named Dr Mikael von Euler chief medical officer. He has more than 20 years' pharmaceutical industry. From 2007-10, he worked at Roche, firstly holding global clinical responsibility for the HER family of compounds, including Herceptin, pertuzumab and Tarceva, and later, as part of the oncology leadership team, acting as a cluster head for the HER2 franchise. Before that, Dr von Euler worked at GlaxoSmithKline and AstraZeneca.